POISE-3
2022
PeriOperative ISchemic Evaluation-3 trial
In 9,535 patients undergoing non-cardiac surgery at risk of bleeding and cardiovascular events, intravenous tranexamic acid reduced life-threatening, major or critical-organ bleeding at 30 days, but non-inferiority for the cardiovascular safety composite was not established compared with placebo.
Result
Efficacy: Composite bleeding outcome at 30 days; safety composite of myocardial injury, stroke, arterial thrombosis or venous thromboembolismHR 0.76 (95% CI 0.67-0.87) · P < 0.001
Safety: Cardiovascular safety compositeHR 1.02 (95% CI 0.92-1.14)
Below 1 favours intravenous tranexamic acid, above 1 favours placebo.
Event rates Intravenous tranexamic acid 9.1% vs placebo 11.7% (composite bleeding outcome at 30 days; safety composite of myocardial injury, stroke, arterial thrombosis or venous thromboembolism)
Also reported: Missing the prespecified non-inferiority margin.
- Subtopic
- Antifibrinolytic therapy
- Design
- Partial factorial, double-blind, placebo-controlled RCT
- Relevance
- Important: one of several pillars.
- Source
- Devereaux PJ, Marcucci M, Painter TW, et al. N Engl J Med. 2022;386(21):1986-1997.doi 10.1056/NEJMoa2201171
Discussion & critique
Non-inferiority for cardiovascular safety formally failed, so a small thrombotic hazard cannot be excluded, and the separately reported blood-pressure-management comparison was neutral. It is by far the largest antifibrinolytic trial in non-cardiac surgery and establishes tranexamic acid as a bleeding-reduction strategy with an explicit thrombotic caveat.